Terms: = Germ cell tumor AND HOXD13, SPD, 3239, P35453, HOX4I AND Treatment
16 results:
1. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract] [Full Text] [Related]
2. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and treatment Regimen.
Malta TM; Sabedot TS; Morosini NS; Datta I; Garofano L; Vallentgoed W; Varn FS; Aldape K; D'Angelo F; Bakas S; Barnholtz-Sloan JS; Gan HK; Hasanain M; Hau AC; Johnson KC; Cazacu S; deCarvalho AC; Khasraw M; Kocakavuk E; Kouwenhoven MCM; Migliozzi S; Niclou SP; Niers JM; Ormond DR; Paek SH; Reifenberger G; Sillevis Smitt PA; Smits M; Stead LF; van den Bent MJ; Van Meir EG; Walenkamp A; Weiss T; Weller M; Westerman BA; Ylstra B; Wesseling P; Lasorella A; French PJ; Poisson LM; ; Verhaak RGW; Iavarone A; Noushmehr H
Cancer Res; 2024 Mar; 84(5):741-756. PubMed ID: 38117484
[TBL] [Abstract] [Full Text] [Related]
3. Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed cell Death Protein PD-1.
Gershtein ES; Mochalova AS; Korotkova EA; Samoilova EV; Vashketova OI; Kuz'min YB; Sokolov NY; Kushlinskii NE
Bull Exp Biol Med; 2023 Aug; 175(4):481-486. PubMed ID: 37773572
[TBL] [Abstract] [Full Text] [Related]
4. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Serratì S; Di Fonte R; Porcelli L; De Summa S; De Risi I; Fucci L; Ruggieri E; Marvulli TM; Strippoli S; Fasano R; Rafaschieri T; Guida G; Guida M; Azzariti A
J Exp Clin Cancer Res; 2023 Sep; 42(1):251. PubMed ID: 37759291
[TBL] [Abstract] [Full Text] [Related]
5. Combined Radiomodifying Effect of Fucoidan from the Brown Alga
Malyarenko OS; Malyarenko TV; Usoltseva RV; Kicha AA; Ivanchina NV; Ermakova SP
Biomolecules; 2023 Feb; 13(3):. PubMed ID: 36979354
[TBL] [Abstract] [Full Text] [Related]
6. Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages.
Liu X; Li Z; Sun J; Zhang Z; Li W
BMC Cancer; 2023 Mar; 23(1):259. PubMed ID: 36941554
[TBL] [Abstract] [Full Text] [Related]
7. Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear spd-L1 for immunotherapy.
Davidson TM; Foster N; Lucien F; Markovic S; Dong H; Winters JL; Park SS; Orme JJ
BMJ Open; 2022 May; 12(5):e050112. PubMed ID: 35551087
[TBL] [Abstract] [Full Text] [Related]
8. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract] [Full Text] [Related]
9. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Mair MJ; Ilhan-Mutlu A; Pajenda S; Kiesel B; Wöhrer A; Widhalm G; Dieckmann K; Marosi C; Wagner L; Preusser M; Berghoff AS
Cancer Immunol Immunother; 2021 Dec; 70(12):3643-3650. PubMed ID: 33956203
[TBL] [Abstract] [Full Text] [Related]
10. A novel miR-7156-3p-hoxd13 axis modulates glioma progression by regulating tumor cell stemness.
Zhang J; Deng M; Tong H; Xue W; Guo Y; Wang J; Chen L; Wang S
Int J Biol Sci; 2020; 16(16):3200-3209. PubMed ID: 33162825
[TBL] [Abstract] [Full Text] [Related]
11. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
[TBL] [Abstract] [Full Text] [Related]
12. Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine tumors: Are Combined Procedures Justified?
Thiels CA; Bergquist JR; Laan DV; Croome KP; Smoot RL; Nagorney DM; Thompson GB; Kendrick ML; Farnell MB; Truty MJ
J Gastrointest Surg; 2016 May; 20(5):891-8. PubMed ID: 26925796
[TBL] [Abstract] [Full Text] [Related]
13. Functional dissection of HOXD cluster genes in regulation of neuroblastoma cell proliferation and differentiation.
Zha Y; Ding E; Yang L; Mao L; Wang X; McCarthy BA; Huang S; Ding HF
PLoS One; 2012; 7(8):e40728. PubMed ID: 22879880
[TBL] [Abstract] [Full Text] [Related]
14. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
[TBL] [Abstract] [Full Text] [Related]
15. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.
Furuta J; Nobeyama Y; Umebayashi Y; Otsuka F; Kikuchi K; Ushijima T
Cancer Res; 2006 Jun; 66(12):6080-6. PubMed ID: 16778180
[TBL] [Abstract] [Full Text] [Related]
16. Mechanism of spermidine uptake in cultured mammalian cells and its inhibition by some polyamine analogues.
Khan NA; Quemener V; Seiler N; Moulinoux JP
Pathobiology; 1990; 58(3):172-8. PubMed ID: 1699552
[TBL] [Abstract] [Full Text] [Related]
